Hans Schikan

Biography

  Hans Schikan is former CEO of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. Prosensa was listed on NASDAQ (RNA) since June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 mln. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles, including as Vice President for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Hans is currently Independent Member of the Supervisory Board of Prosensa Holding (Netherlands), Chairman of the Board of Complix (Belgium) and of Asceneuron (Switzerland), Board Member of Hansa Medical (publ, Sweden), Non-executive Director of Sobi (Swedish Orphan Biovitrum, publ, Sweden), Board Member of Wilson Therapeutics (Sweden) and Member of the Top Team of the Dutch Top Sector Life Sciences & Health (Netherlands). He is Adviser of Khondrion (Netherlands) and the Leiden BioScience Park (Netherlands), past Chairman of Nefarma, the Dutch Association of Research Based Pharmaceutical Industry and he was previously also Member of the Biotechnology Industry Organization’s Emerging Companies Section Governing Board (USA). He has a PharmD from Utrecht University.

Research Interest

  RNA modulating